# US 2010/0074949 A1 · Pharmaceutical composition and administration thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074949 A1
- Document ID: US20100074949A1
- Status: Published application
- Kind: A1
- Application number: 12/583,066
- Filed: 2009-08-13
- Published: 2010-03-25
- Earliest claimed: 2008-08-13
- Inventors: William Rowe; Patricia Hurter; Christopher Young; Kirk Dinehart; Marinus Jacobus Verwijs; Kirk Overhoff; Peter D.J. Grootenhuis; Martyn Botfield; Alfredo Grossi
- Web page: https://patentgrep.com/patent/US20100074949A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/08: Bronchodilators
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

## Claims

### Claim at position 1

1-111. (canceled)

### Claim 112

A pharmaceutical composition comprising:
a. a solid dispersion comprising substantially amorphous Compound 1 and a polymer;
b. a filler;
c. a disintegrant;
d. a surfactant;
e. a binder;
f. a glidant; and
g. a lubricant.

### Claim 113 (depends on 112)

The pharmaceutical composition of claim 112, wherein the solid dispersion comprises substantially amorphous Compound 1 and a polymer, and the polymer comprises HPMC, HPMCAS, PVP/VA, PVP, methacrylic acid/methacrylate copolymer, HPC, or any combination thereof.

### Claim 114 (depends on 113)

The pharmaceutical composition of claim 113, wherein the solid dispersion has a mean particle diameter of greater than about 5 μm.

### Claim 115 (depends on 113)

The pharmaceutical composition of claim 113, wherein the solid dispersion has a bulk density of about 0.10 g/cc or greater.

### Claim 116 (depends on 113)

The pharmaceutical composition of claim 113, wherein the solid dispersion comprises substantially amorphous Compound 1, and Compound 1 is present in a concentration of at least 20 wt % by weight of the solid dispersion.

### Claim 117 (depends on 116)

The pharmaceutical composition of claim 116, wherein the solid dispersion comprises 80 wt % or less of HPMCAS or PVP/VA.

### Claim 118 (depends on 116)

The pharmaceutical composition of claim 116, wherein the solid dispersion further comprises a surfactant.

### Claim 119 (depends on 118)

The pharmaceutical composition of claim 118, wherein the solid dispersion comprises less than 10 wt % of surfactant by weight of solid dispersion.

### Claim 120 (depends on 119)

The pharmaceutical composition of claim 119, wherein the surfactant is SLS.

### Claim 121 (depends on 120)

The pharmaceutical composition of claim 120, wherein the solid dispersion comprises amorphous Compound 1.

### Claim 122 (depends on 112)

The pharmaceutical composition of claim 112, wherein the solid dispersion comprises from about 45 wt % to about 85 wt % of substantially amorphous Compound 1, from about 0.45 wt % to about 0.55 wt % of SLS, and from about 14.45 wt % to about 55.55 wt % of HPMCAS or PVP/VA by weight of the solid dispersion.

### Claim 123 (depends on 112)

The pharmaceutical composition of claim 112, wherein the filler is lactose, sorbitol, cellulose, calcium phosphate, starch, sugar, or any combination thereof.

### Claim 124 (depends on 123)

The pharmaceutical composition of claim 123, wherein the filler is lactose and has a concentration of at least about 10 wt % by weight of the composition.

### Claim 125 (depends on 112)

The pharmaceutical composition of claim 112, wherein the disintegrant is sodium croscarmellose, sodium starch glycolate, or a combination thereof.

### Claim 126 (depends on 125)

The pharmaceutical composition of claim 125, wherein the disintegrant is sodium croscarmellose and has a concentration of about 10 wt % or less by weight of the composition.

### Claim 127 (depends on 112)

The pharmaceutical composition of claim 112, wherein the surfactant is sodium lauryl sulfate, sodium stearyl fumarate, polyoxyethylene 20 sorbitan mono-oleate, or any combination thereof.

### Claim 128 (depends on 127)

The pharmaceutical composition of claim 127, wherein the surfactant is sodium lauryl sulfate and has a concentration of about 10 wt % or less by weight of the composition.

### Claim 129 (depends on 112)

The pharmaceutical composition of claim 112, wherein the binder is microcrystalline cellulose, dibasic calcium phosphate, sucrose, corn starch, modified cellulose, or any combination thereof.

### Claim 130 (depends on 129)

The pharmaceutical composition of claim 129, wherein the binder is microcrystalline cellulose and has a concentration of at least about 1 wt % by weight of the composition.

### Claim 131 (depends on 112)

The pharmaceutical composition of claim 112, wherein the glidant is colloidal silicon dioxide, talc, or a combination thereof.

### Claim 132 (depends on 131)

The pharmaceutical composition of claim 131, wherein the glidant is colloidal silicon dioxide and has a concentration of 2 wt % or less by weight of the composition.

### Claim 133 (depends on 112)

The pharmaceutical composition of claim 112, wherein the lubricant is magnesium stearate, stearic acid, hydrogenated oil, sodium stearyl fumarate, or any combination thereof.

### Claim 134 (depends on 133)

The pharmaceutical composition of claim 133, wherein the lubricant is magnesium stearate and has a concentration of about 2 wt % by weight of the composition.

### Claim 135 (depends on 112)

The pharmaceutical composition of claim 112 further comprising a colorant.

### Claim 136 (depends on 135)

The pharmaceutical composition of claim 135, wherein the colorant is a blue pigment having a concentration of about 3wt % by weight of the composition.

### Claim 137 (depends on 136)

The pharmaceutical composition of claim 136, wherein the composition is formed into a tablet and the tablet comprises the colorant as a tablet coating.

### Claim 138 (depends on 137)

The pharmaceutical composition of claim 137, wherein the blue pigment is OPADRY®II.

### Claim 139 (depends on 135)

The pharmaceutical composition of claim 135 further comprising a wax.

### Claim 140 (depends on 139)

The pharmaceutical composition of claim 139, wherein the wax comprises Carnauba wax powder.

### Claim 141

A pharmaceutical composition comprising
a. from about 5 wt % to about 50 wt % of a solid dispersion, by weight of the composition, comprising from about 70 wt % to about 90 wt % of substantially amorphous Compound 1, by weight of the dispersion, and from about 30 wt % to about 10 wt % of a polymer, by weight of the dispersion;
b. from about 25 wt % to about 50 wt % of a filler;
c. from about 1 wt % to about 10 wt % of a disintegrant;
d. from about 2 wt % to about 0.3 wt % of a surfactant;
e. from about 5 wt % to about 50 wt % of a binder;
f. from about 2 wt % to about 0.05 wt % of a glidant; and
h. from about 2 wt % to about 0.1 wt % of a lubricant.

### Claim 142 (depends on 141)

The pharmaceutical composition of claim 141, wherein the composition is formed as a tablet, a capsule, or a suspension.

### Claim 143 (depends on 142)

The pharmaceutical composition of claim 142, wherein the composition is formed as a tablet and the tablet has a hardness of at least 5 Kp.

### Claim 144 (depends on 143)

The pharmaceutical composition of claim 143, wherein the tablet has a dissolution of at least about 50% in about 30 minutes, and the solid dispersion comprises substantially amorphous Compound 1.

### Claim 145 (depends on 144)

The pharmaceutical composition of claim 144, wherein the solid dispersion comprises substantially amorphous Compound 1 and HPMCAS.

### Claim 146

A pharmaceutical composition consisting of a tablet comprising
a. a solid dispersion comprising from about 20 wt % to about 99 wt % of substantially amorphous Compound 1 by weight of the dispersion and HPMCAS;
b. from about 27 wt % to about 45 wt % of a filler comprising lactose;
c. from about 2.5 wt % to about 6.0 wt % of a disintegrant comprising sodium croscarmellose;
d. from about 2.0 wt % to about 0.3 wt % of a surfactant comprising sodium lauryl sulfate;
e. from about 20 wt % to about 45 wt % of a binder comprising microcrystalline cellulose;
f. from about 1.0 wt % to about 0.09 wt % of a glidant comprising colloidal silicon dioxide; and
g. from about 1.3 wt % to about 0.3 wt % of a lubricant comprising magnesium stearate.

### Claim 147 (depends on 146)

The pharmaceutical composition of claim 146, wherein the composition comprises a. about 34.1 wt % of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt % of substantially amorphous Compound 1 by weight of the dispersion, about 19.5 wt % of HPMCAS by weight of the dispersion, and about 0.5 wt % SLS by weight of the dispersion;
b. about 30.5 wt % of microcrystalline cellulose by weight of the composition;
c. about 30.4 wt % of lactose by weight of the composition;
d. about 3 wt % of sodium croscarmellose by weight of the composition;
e. about 0.5 wt % of SLS by weight of the composition;
f. about 0.5 wt % of colloidal silicon dioxide by weight of the composition; and
g. about 1.0 wt % of magnesium stearate by weight of the composition.

### Claim 148 (depends on 147)

The pharmaceutical composition of claim 147, wherein the tablet further comprises a coating.

### Claim 149 (depends on 148)

The pharmaceutical composition of claim 148, wherein the coating comprises a colorant.

### Claim 150 (depends on 149)

The pharmaceutical composition of claim 149, wherein the colorant comprises OPADRY® H.

### Claim 151 (depends on 150)

The pharmaceutical composition of claim 150, wherein the coating further comprises a wax coating.

### Claim 152 (depends on 151)

The pharmaceutical composition of claim 151, wherein the wax coating comprises a Carnauba wax powder.

### Claim 153 (depends on 152)

The pharmaceutical composition of claim 152, wherein the tablet further comprises ink images or ink text printed on the coating.

### Claim 154 (depends on 147)

The pharmaceutical composition of claim 147, wherein the tablet has a hardness of about 10 Kp±20 percent.

### Claim 155 (depends on 147)

The pharmaceutical composition of claim 147, wherein the tablet contains about 150 mg of Compound 1.

### Claim 156 (depends on 147)

The pharmaceutical composition of claim 147, wherein the tablet contains about 100 mg of Compound 1.

### Claim 157

A method of producing a pharmaceutical composition comprising providing an admixture comprising:
a. a solid dispersion comprising substantially amorphous Compound 1;
b. a binder;
c. a glidant;
d. a surfactant;
e. a lubricant;
f. a disintegrant; and
g. a filler, and
compressing the admixture into a tablet having a dissolution of at least about 50% in about 30 minutes.

### Claim 158 (depends on 157)

The method of claim 157, wherein the admixture is compressed to produce a tablet having a hardness of at least 5 Kp.

### Claim 159 (depends on 157)

The method of claim 157, further comprising mixing the admixture until the admixture is substantially homogenous.

### Claim 160

A method of administering a pharmaceutical composition comprising orally administering to a patient at least once per day at least one tablet comprising:
a. a solid dispersion comprising from about 20 wt % to about 99 wt % of substantially amorphous Compound 1 by weight of the dispersion and HPMCAS;
b. from about 27 wt % to about 45 wt % of a filler comprising lactose;
c. from about 2.5 wt % to about 6.0 wt % of a disintegrant comprising sodium croscarmellose;
d. from about 2.0 wt % to about 0.3 wt % of a surfactant comprising sodium lauryl sulfate;
e. from about 20 wt % to about 45 wt % of a binder comprising microcrystalline cellulose;
f. from about 1.0 wt % to about 0.09 wt % of a glidant comprising colloidal silicon dioxide; and
g. from about 1.3 wt % to about 0.3 wt % of a lubricant comprising magnesium stearate.

### Claim 161 (depends on 160)

The method of claim 160, wherein the composition comprises
a. about 34.1 wt % of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt % of substantially amorphous Compound 1 by weight of the dispersion, about 19.5 wt % of HPMCAS by weight of the dispersion, and about 0.5 wt % SLS by weight of the dispersion;
b. about 30.5 wt % of microcrystalline cellulose by weight of the composition;
c. about 30.4 wt % of lactose by weight of the composition;
d. about 3 wt % of sodium croscarmellose by weight of the composition;
e. about 0.5 wt % of SLS by weight of the composition;
f. about 0.5 wt % of colloidal silicon dioxide by weight of the composition; and
g. about 1.0 wt % of magnesium stearate by weight of the composition.

### Claim 162 (depends on 161)

The method of claim 161, wherein the tablet contains about 150 mg of Compound 1.

### Claim 163 (depends on 162)

The method of claim 162, wherein the tablet contains about 100 mg of Compound 1.

### Claim 164 (depends on 161)

The method of claim 161, wherein the tablet is orally administered to the patient once per day or about every 12 hours.

### Claim 165 (depends on 164)

The method of claim 164, wherein the tablet is orally administered about every 12 hours.

### Claim 166 (depends on 112)

A method of treating or lessening the severity of a disease in a patient comprising administering to said patient a pharmaceutical composition according to claim 112, wherein said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia; including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.

### Claim 167 (depends on 147)

A method of treating or lessening the severity of a disease in a patient comprising administering to said patient a pharmaceutical composition according to claim 147, wherein said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.

### Claim 168 (depends on 167)

The method of claim 167, wherein said disease is cystic fibrosis.

### Claim 169 (depends on 168)

The method of claim 168, wherein said patient has cystic fibrosis transmembrane receptor (CFTR) with a ΔF508 mutation.

### Claim 170 (depends on 168)

The method of claim 168, wherein said patient has cystic fibrosis transmembrane receptor (CFTR) with a R117H mutation.

### Claim 171 (depends on 168)

The method of claim 168, wherein said patient has cystic fibrosis transmembrane receptor (CFTR) with a G551D mutation.
